ReviewFrontiers in cardiovascular medicine2025
ELABELA: a polypeptide with therapeutic potential in cardiovascular diseases.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Elabela in Lipid-Related Cardiometabolic Dysfunction: A Critical Narrative Review.Metabolites · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) are an increasingly common public health problem, and their diagnosis and treatment continue to face serious challenges, making it necessary to explore new therapeutic approaches. The small molecule polypeptide ELABELA (ELA) plays an important role in CVDs. We aim to review the role of ELA in cardiovascular development and its related mechanisms, as well as its diagnostic value and therapeutic potential in CVDs, including preeclampsia, hypertension, vascular calcification, various heart diseases, and ischemia-reperfusion injury. ELA can be used as a diagnostic marker for CVDs and has been demonstrated to reduce oxidative stress, cell apoptosis, tissue fibrosis, and vascular hypertension and promote angiogenesis. This suggests that ELA may serve as both a diagnostic and treatment target. This review provides some strategies for the diagnosis and treatment of small molecule polypeptide ELA in CVDs and the development of targeted drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.